U.S. Markets close in 6 hrs 15 mins

OraSure Technologies, Inc. (OSUR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.48+0.03 (+0.55%)
As of 04:00PM EDT. Market open.

OraSure Technologies, Inc.

220 East First Street
Bethlehem, PA 18015
United States
610 882 1820

IndustryMedical Instruments & Supplies
Full Time Employees785

Key Executives

NameTitlePayExercisedYear Born
Dr. Nancy J. Gagliano M.B.A., M.D.Interim CEO & Director8.62kN/A1960
Mr. Scott GleasonSr. VP of Investor Relations & Corp. Communications and Interim CFO362.92kN/A1979
Ms. Agnieszka M. Gallagher J.D.Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.542.44kN/A1974
Ms. Kathleen Gallagher WeberPres of Molecular Solutions1.12MN/A1968
Ms. Michele Marie MillerSr. VP, Chief Accounting Officer, Controller & Assistant Sec.N/AN/A1974
Mr. David A. Rappaport C.F.A., CFASr. VP Corp. Devel., Strategy & IntegrationN/AN/AN/A
Amy SteigerwaltVP of HRN/AN/AN/A
Ms. Lisa NibauerPres of DiagnosticsN/AN/A1969
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

Corporate Governance

OraSure Technologies, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 4. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.